VanEck Vectors Pharmaceutical ETF (PPH)

64.45 +1.74  +2.77% NASDAQ Jul 15, 20:00 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 64.40
Discount or Premium to NAV 0.08%
Turnover Ratio 21.00%
1 Year Fund Level Flows --

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 6.95% 6.83% 7.54% 93
3M 11.94% 11.74% 15.22% 95
6M -2.27% -2.39% 6.48% 94
YTD 1.48% 1.31% 7.69% 92
1Y 14.13% 14.06% 20.34% 91
3Y 5.10% 5.08% 11.30% 91
5Y -0.70% -0.71% 6.05% 95
10Y -- -- 15.92% --
15Y -- -- 11.17% --
20Y -- -- 9.02% --
As of July 15, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash -0.07% 0.00% 0.07%
Stock 100.1% 100.1% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of July 14, 2020

Region Exposure

Americas 60.32%
North America 60.32%
Latin America 0.00%
Greater Europe 35.53%
United Kingdom 15.25%
Europe Developed 15.88%
Europe Emerging 0.00%
Africa/Middle East 4.41%
Greater Asia 4.15%
Japan 4.15%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.00%
% Emerging Markets 0.00%
As of July 14, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of July 14, 2020

Stock Market Capitalization

Giant 58.82%
Large 8.88%
Medium 30.34%
Small 1.95%
Micro 0.00%
As of July 14, 2020

Stock Style Exposure

Large Cap Value 45.50%
Large Cap Blend 15.17%
Large Cap Growth 9.30%
Mid Cap Value 21.61%
Mid Cap Blend 0.00%
Mid Cap Growth 7.77%
Small Cap Value 0.64%
Small Cap Blend 0.00%
Small Cap Growth 0.00%
As of July 14, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
LLY Eli Lilly and Co 5.47% 165.00 -0.27%
ABBV AbbVie Inc 5.14% 99.88 -0.60%
SNY Sanofi SA ADR 5.09% 53.25 -0.04%
AZN AstraZeneca PLC ADR 5.07% 57.26 -1.28%
JNJ Johnson & Johnson 5.04% 148.94 +0.46%
NVS Novartis AG ADR 5.01% 87.14 -0.83%
PFE Pfizer Inc 4.94% 35.68 -0.11%
BMY Bristol-Myers Squibb Company 4.85% 59.00 -0.46%
GSK GlaxoSmithKline PLC ADR 4.83% 41.69 -0.62%
MRK Merck & Co Inc 4.82% 79.23 -0.26%
As of July 14, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Value
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name VanEck
Benchmark Index
MVIS US Listed Pharmaceutical 25 NR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Guo Hua (Jason) Jin 2.41 yrs
Hao-Hung (Peter) Liao 8.54 yrs

Net Fund Flows

1M 0.00
3M 25.75M
6M 29.03M
YTD 29.03M
1Y --
3Y --
5Y --
10Y --
As of June 30, 2020

Risk Info

Beta (5Y) 0.9371
Max Drawdown (All) 30.19%
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) 0.7418
30-Day Rolling Volatility 23.45%
Daily Value at Risk (VaR) 1% (All) 2.92%
Monthly Value at Risk (VaR) 1% (All) 12.22%

Fundamentals

Dividend Yield TTM (7-15-20) 1.64%
30-Day SEC Yield (6-30-20) 1.62%
7-Day SEC Yield --
Weighted Average PE Ratio 25.78
Weighted Average Price to Sales Ratio 0.8720
Weighted Average Price to Book Ratio 2.881
Weighted Median ROE 25.14%
Weighted Median ROA 6.49%
Forecasted Dividend Yield 2.35%
Forecasted PE Ratio 12.32
Forecasted Price to Sales Ratio 0.8280
Forecasted Price to Book Ratio 2.855
Number of Holdings 26
As of July 14, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 7.33%
Forecasted Book Value Growth -5.87%
Forecasted Cash Flow Growth -7.79%
Forecasted Earnings Growth 0.15%
Forecasted Revenue Growth 6.64%
As of July 14, 2020

Comparables

Edit

Attributes

Key Dates
Inception Date 12/20/2011
Termination Date
Last Annual Report Date 9/30/2019
Last Prospectus Date 1/31/2020
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.